Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P21
Within normal range
vs 2Y Ago
-29.1x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -36.11% |
| Q2 2025 | -35.40% |
| Q1 2025 | 8.47% |
| Q4 2024 | 95.96% |
| Q3 2024 | -37.41% |
| Q2 2024 | 99.31% |
| Q1 2024 | 74.18% |
| Q4 2023 | 48.03% |
| Q3 2023 | 1.24% |
| Q2 2023 | -92.55% |
| Q1 2023 | 2680.03% |
| Q4 2022 | 106.39% |
| Q3 2022 | -72.12% |
| Q2 2022 | 1032.33% |
| Q1 2022 | 0.00% |